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Abstract This tutorial summarises the state-of-the-art on
migraine genetics and looks at the possible future direction
of this field of research. The view of migraine as a genetic
disorder, initially based on epidemiological observations of
transmission of the condition within families, was subse-
quently confirmed by the identification of monogenic forms
of ‘‘syndromic’’ migraine, such as familial hemiplegic
migraine. We are currently witnessing a change in the way
genetic analysis is used in migraine research: rather than
studying modalities of inheritance in non-monogenic forms
of migraine and in the persistent modalities of migraine
headache, researchers are now tending to focus on the search
for genetic markers of dysfunction in biological systems. One
example of the evolution of migraine genetic research is
provided by the recent efforts to shed light on the pharmac-
ogenomic mechanisms of drug response in migraineurs. In
addition, novel molecular approaches about to be introduced
are expected to further increase knowledge on this topic and
improve patient management.
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Introduction
Migraine is a common disorder characterised by recurrent
disabling attacks of headache associated with nausea,
vomiting, hypersensitivity to light, sound, and smell
(migraine without aura, MO), and, in about 25 % of cases,
neurological aura symptoms (migraine with aura, MA) [1,
2]. Aura symptoms, which generally include visual dis-
turbances, last for up to an hour but can sometimes last for
several days. Rarely, focal motor seizures may occur as
part of the aura spectrum [1]. Patients with at least one MA
attack per month show a higher risk for brain lesions [3].
The neurobiological mechanism underlying migraine aura
is cortical spreading depression [4].
Migraine is a major cause of non-fatal disease-related
disability [5], being estimated to affect about 12 % of the
Western population. The disease is more frequent in
females (3:1 female-to-male ratio) and has its peak prev-
alence between the ages of 22 and 55 years [5, 6]. Overall,
MA prevalence is 1–4 % in the male population and
3–10 % in the female population [6].
Onset of the disease may occur in childhood or even
infancy, and according to international guidelines, more
than 30 % of migraineurs are candidates for preventive
therapy. In general, migraine has a profound effect on
wellbeing and general functioning, not only during attacks
but also in terms of work performance, family and social
relationships, and school achievement [2].The WHO rates
it among the most disabling, and costly, chronic disorders
[7]. Nonetheless, it is generally estimated that about 30 %
C. Di Lorenzo
Don Carlo Gnocchi Onlus Foundation, Rome, Italy
G. S. Grieco
Laboratory of Neurogenetics, C. Mondino National
Institute of Neurology Foundation, IRCCS, Pavia, Italy
F. M. Santorelli
Molecular Medicine and Neurodegenerative
Diseases-IRCCS Stella Maris, Pisa, Italy
F. M. Santorelli
Child Neurology, University of Pisa, Pisa, Italy
F. M. Santorelli (&)
Molecular Medicine, IRCCS Stella Maris,
via dei Giacinti 2, 56128 Calambrone, Pisa, Italy
e-mail: filippo3364@gmail.com
123
J Headache Pain (2012) 13:571–580
DOI 10.1007/s10194-012-0478-x
of affected individuals do not receive a correct diagnosis
and are likely to remain inadequately treated, or even
misdiagnosed throughout their lives [8]. Prophylactic drug
treatment of migraine should be considered in a series of
situations: when quality of life, work commitments, or
school attendance are severely impaired; when the fre-
quency of attacks per month is two or higher; when
migraine attacks do not respond to acute drug treatment;
when patients experience frequent, very long, or uncom-
fortable auras [2].
The common observation that migraine tends to run in
families has long been the basis for suggesting that genetic
determinants play a significant role in the disease. It has
been shown that at least 50 % of migraineurs have a parent
affected by a similar condition and a familial liability has
been confirmed in several studies, especially ones com-
paring concordance rates between monozygotic and dizy-
gotic twins (as recently reviewed [9]). Although familial
does not necessarily mean genetic, epidemiological evi-
dence seems to indicate a close gene–environment inter-
action, at least in MA. The possible role of brain energy
through oxidative metabolism has also been invoked [10].
Deeper insight into the possible molecular genetic contri-
bution to migraine has come from the study of rarer,
monogenic forms of ‘‘syndromic’’ migraine, such as
familial hemiplegic migraine (FHM), as well as from the
use of technically improved molecular methods.
The aim of this paper is to briefly review current
molecular genetic evidence in both MA and MO, focusing
on recent data from whole-genome studies; we will also
consider the outlook for research in this field, destined to
be driven by constant advances in gene/genome sequencing
technology. A useful technical ‘‘glossary’’ is shown in
Table 1.
Monogenic forms of migraine: familial hemiplegic
migraine
The most straightforward approach for identifying genes
and unravelling genetic pathways involved in complex
genetic disorders is to study monogenic subtypes of the
same disorders. Familial hemiplegic migraine (FHM), a
rare form of migraine with motor aura, is an example of a
monogenic subtype of migraine which can be considered a
model for the common forms of the disease, because, with
the exception of the hemiparesis, it presents with exactly
the same headache and aura features [11]. In FHM, the
Table 1 Glossary of useful ‘‘technical’’ terminology
Genotype It is the state of the pairs of alleles present at one or more loci associated with a given trait
Phenotype It refers to the observable state of the trait (e.g. blue eyes, red hair)
Dominant It refers to mutations at a given locus occurring in a heterozygote status
Recessive It refers to mutations occurring in homozygosity
Loss of function It refers to the functional consequences of mutations on protein function. It indicates that the amount of normal protein
is decreased (as seen in inborn errors of metabolism)
Gain of function It refers to the functional consequences of mutations on protein function. It indicates the case of abnormal gene dosage,
as in trisomy of chromosome 21, or when mutations result in a negative effect on normal protein function)
Inappropriate
expression
It indicates abnormal protein expression as can often be seen for oncogenes
Incomplete or no
penetrance
It is the case of individuals who may only partly display the characteristic disease phenotype
Variable expression It is the variable consequence of gene mutation on clinical phenotype. It is believed to be due to allelic/locus
heterogeneity or to the effects of modifier genes (or even environmental or metabolic factors)
Incomplete dominance It refers to the blending of traits that occurs when two different alleles of a gene pair occur together and neither is
dominant
Co-dominance It refers to the condition in which both the alleles in a gene pair are fully expressed, without one being dominant over
the other (this results in a third, novel phenotype)
Polygenic inheritance This non-Mendelian inheritance is determined by the alleles of more than one gene. The more genes involved, the
greater the number of intermediate phenotypes that will be produced. This modality occurs with a sort of additive
effect and the picture becomes even more variegated when the multiple genes interact with environmental factors
Cytoplasmic
transmission
Another aspect of non-Mendelian inheritance that occurs in the case of variants in the mitochondrial genome
(mtDNA). MtDNA is a circular, double-stranded, 16.569 base-pair molecule of DNA which encodes 13 essential
polypeptides for the oxidative phosphorylation (OXPHOS) system, two ribosomal RNAs, and 22 tRNAs. The
mitochondrial genome is strictly maternally inherited and there are several hundred to several thousands of copies
within a single cell [10]. The number of copies present varies between different cell types, depending on the energy
demand within the tissue, and it is extremely high in neurons [10]
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symptoms include both typical migraine attacks and severe
episodes with prolonged aura and impaired consciousness,
ranging from confusion to profound coma. In some cases,
attacks can be triggered by minor head trauma [12], and in
others, epilepsy may be a co-morbid condition or occur
during a hemiplegic attack. In 20 % of families, patients
also have fixed cerebellar symptoms and signs, such as
nystagmus and progressive ataxia. A clearer link with
common forms of MA and MO has emerged in patients
without a proven or suspected family history (sporadic
hemiplegic migraine, SHM). In a large Danish population-
based study, an increased risk of MA and MO was dem-
onstrated in first-degree relatives of SHM patients [13].
Although FHM and MA share many similarities on clinical
grounds, it remains unclear whether and to what extent
they are pathophysiologically related. To date, three
genes—two ion-channel genes and one encoding an ATP
exchanger—have been found to underlie FHM. CACNA1A
(FHM1), located on chromosome 19p13 [14], was the first
FHM gene identified and approximately 70 different causal
missense mutations have been detected in it. Besides FHM,
these mutations can be associated with episodic cerebellar
ataxia type 2, cerebellar ataxia type 6 (SCA6) [15], and
episodic seizures and migraine with motor regression [16].
CACNA1A encodes the a1 subunit of neuronal CaV2.1 (P/
Q-type) voltage-gated calcium channels that are widely
expressed throughout the central nervous system [17]. This
subunit is involved in voltage sensitivity and mutations
lead to uptake of Ca2? ions into neurons in response to a
smaller depolarisation than is required by wild-type chan-
nels. This, in turn, causes excessive release of the neuro-
transmitter glutamate [18].
The second FHM gene, ATP1A2 (FHM2), is located on
chromosome 1q23 [19] and encodes the a2 subunit of
sodium–potassium pumps. There are now over 40 FHM2
mutations that, with rare exceptions, are private, that is,
they occur in single families. Most of the ATP1A2 muta-
tions are associated with pure FHM, without additional
clinical symptoms [19–23]. However, FHM2 mutations
are increasingly being recognised to be associated with
cerebellar problems [24], childhood convulsions (benign
familial infantile convulsions) [25], epilepsy [20, 26],
alternating hemiplegia of childhood [27], and permanent
mental retardation [20, 28]. Intriguingly, mutations in
ATP1A2 have also been shown to be associated with non-
hemiplegic migraine phenotypes, such as basilar migraine
[29] and even common migraine [30], although this cau-
sality has not been definitively confirmed. The most
recently identified FHM gene is SCN1A (FHM3), located
on chromosome 2q24 [31], which is the site of five known
FHM mutations [32–34]. SCN1A encodes the a1 subunit of
neuronal NaV1.1 voltage-gated sodium channels and is a
well-known epilepsy gene harbouring over 100 truncating
and missense mutations associated with childhood epilepsy
(i.e. severe myoclonic epilepsy of infancy) [35, 36]. It is of
note that two carriers of the FHM3 Q1489H mutation also
suffered from ‘elicited repetitive transient daily blindness’
and childhood epilepsy [37]. There exist forms of typical
FHM not related to mutations in FHM genes and further
heterogeneity is expected to emerge. For instance, a yet
unknown FHM4 gene on chromosome 14, and the possible
FHM5/SLC4A4 and FHM6/SLC1A3 genes encoding met-
abolic transporters are believed to exist (Fig. 1) (reviewed
in [38]) but even more loci/genes are anticipated.
There are no obvious clinical differences between
carriers of mutations in the three genes already known to
cause FHM, although patients with FHM1 mutations
more often exhibit cerebellar ataxia and FHM2 cases
report (minor) head trauma as a trigger of attacks. In
addition, for all three FHM genes, there are mutation
carriers who have epilepsy (or present with it). This is not
particularly surprising given the epidemiological evi-
dence of a bidirectional co-morbidity between migraine
and epilepsy, which suggests that both disorders have, at
least in part, a shared pathophysiology [39]. The identi-
fication of gene mutations that can cause both FHM and
epilepsy would provide a unique opportunity to study
these mechanisms.
Functional studies of FHM mutations
The functional consequences of FHM gene mutations have
been extensively analysed in cellular and animal models.
Studies of heterologous expression of human mutations and
calcium channel functioning using whole-cell electro-
physiology (for review see [40]) have shown that FHM1
mutations increase the opening probabilities of channels,
also at more negative voltages, compared to what is seen in
wild-type channels [41, 42]. It is hypothesised that this
gain-of-function effect results in increased Ca2? influx, and
therefore predicts increased neurotransmission. A similar
Fig. 1 Relative frequency of known forms of familial hemiplegic
migraine (FHM). See text for details
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conclusion was reached in knock-in mice harbouring the
human FHM1 R192Q mutation. The threshold for CSD
was found to be lowered and CSD propagation velocity
increased in FHM1 R192Q mutant mice. These observa-
tions, highly relevant to migraine, indicate that FHM1
mutant mice are useful models for studying the patho-
physiology of the disease in vivo. The functional conse-
quences of a large number of ATP1A2 mutations causing
either FHM or SHM have been investigated in vitro. FHM2
mutations resulted in reduced or absent sodium potassium
pump activity with decreased (in the case of T345A and
A606T variants) or increased (in some other cases) affinity
for potassium [43–45]. Thus, the consequence of FHM2
mutations is a loss-of-function mechanism with non-func-
tional proteins impairing pump function. Unfortunately, it
has not proved possible to reproduce these cell data in
animal models that lack the a2-subunit, because Atp1a2
knockout mice have a severe phenotype and die immedi-
ately after birth because of their inability to start breathing
[46]. The functional consequences of FHM3 mutations
have been investigated both in heterologous systems [31,
32] and in cultured neurons [47], and both gain- and loss-
of-function mechanisms have been observed.
On the basis of the aforementioned observations, it is
tempting to hypothesise a unifying mechanism for FHM,
able to explain at least the issues related to CSD. Mutant
CaV2.1 calcium channels might predict increased gluta-
mate release in the cerebellar cortex, and accordingly, more
easily induce, maintain, and propagate CSD [18]. FHM2
mutations predict reduced glial uptake of K? and glutamate
from the synaptic cleft whereas FHM3 mutations are
expected to be associated with hyperexcitability of excit-
atory neurons. Thus, the predicted consequence of FHM1,
FHM2, and FHM3 mutations is increased levels of gluta-
mate and potassium in the synaptic cleft (see also Fig. 2).
High glutamate and potassium conditions suggest an
increased propensity for CSD which would provide a good
explanation of the aura. It remains debatable, and largely
Fig. 2 Possible consequences of migraine mutations affecting the
central glutamate synapse. Increased Ca2? influx caused by mutations
in familial hemiplegic migraine subtype 1 (FHM1) encoding Cav2.1
channels enhance glutamate release from presynaptic terminals. Loss
of Na?/K? ATPase function, occurring in FHM2, also reduces
astrocyte uptake of glutamate leading to increased levels of the
neurotransmitter in the synaptic cleft. The mutations in FHM3 can
reduce firing of inhibitory interneurons or potentiate presynaptic
action potential generation. Mutations in FHM5/SLC4A4 might
inhibit glia-mediated acid secretion and thus free N-methyl-D-
aspartate (NMDA) receptors from proton-mediated inhibition. Activ-
ity of EAAT1, the major glutamate transporter in the brain encoded
by FHM6/SLC1A3, is directly affected by a mutation in its sequence
and indirectly by a reported mutation in rs1835740, a variant located
between MTDH and PGCP which might be up-regulated). The LRP1
gene has a role in glutamate signalling and the consequence of a
reported mutation in rs11172113 might directly modulate NMDA-
dependent calcium currents in vitro
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unclear, whether this also results in a more readily acti-
vated trigemino-vascular system, and is therefore sufficient
to explain the headache.
As the main clinical symptoms of headache and aura are
similar in FHM and common migraine, it is thought that
they may share a common pathophysiology [48]. Several
studies have investigated (with conflicting results) the role
of FHM1 and FHM2 loci/genes in the common forms of
migraine since the early description of the CACNA1A
gene in the late 90s. Variants in FHM3 are far less inves-
tigated. In short [49], these studies led to the conclusion
that common variants in ion transport genes do not play a
major role in susceptibility to common migraine. However,
the possible role of rarer variants or variants with a smaller
effect size cannot at present be predicted.
Other forms of syndromic migraine
Excluding a major role for FHM genes in the aetiology of
common forms of migraine does not mean that ion chan-
nels are not important to understanding of the pathogenesis
of typical attacks. The same applies to other forms of
‘‘syndromic’’ migraine (see Table 2), all characterised by
headache attacks of the migraine type. Clinical conditions
such as cerebral autosomal dominant arteriopathy with
subcortical infarcts and leukoencephalopathy (CADASIL)
or mitochondrial DNA-related disorders, such as MELAS
(mitochondrial encephalopathy with lactic acidosis and
stroke-like episodes) may well shed light on important
steps in the pathophysiology of aura or CSD but are less
likely to account for a significant proportion of typical
migraine attacks, even though headache pain is common
among the plethora of neurological manifestations of both
conditions. CADASIL is a brain microangiopathy due to
mutations in the NOTCH3 gene and it is characterised by
stroke-like episodes, cognitive decline, MA (in about 35 %
of cases), psychiatric disorders, and epilepsy [50]. Ischae-
mic attacks in CADASIL occurring during pregnancy and
puerperium are more frequent in women aged over
30 years [51]. Additional symptoms include reversible
acute encephalopathy [52], subclinical peripheral neurop-
athy, subclinical retinal vascular abnormalities [53], and
occasionally acute myocardial infarction [54]. It remains
possible that NOTCH3 variants per se, or in combination
with other functional modifications in an adjacent gene yet
to be identified, are able to influence subtypes of migraine.
Interestingly, it has been shown a positive allelic and
genotypic association between a polymorphic variant in
NOTCH3 (namely, rs 1043994, c.684G[A) and MA in two
independent population [55].
MELAS is often associated with the mtDNA A-to-G
transition at nucleotide 3243 and clinical features include
seizures, hemiparesis, hemianopsia, cortical blindness,
migraine and episodic vomiting [56]. In addition, systemic
manifestations of MELAS, including cardiac, renal, endo-
crine, gastrointestinal, and endothelial abnormalities have
been reported. Vascular system involvement has been
highlighted in both conditions, and decreased oxidative
brain metabolism has been shown to play a pivotal role in
the pathogenesis of migraine [57].
Linkage analyses and genome-wide association
studies in common migraine
The involvement of three major genes in syndromic
migraine is not paralleled by equally common aetiologies
in common migraine, which suggests that other genetic
approaches are needed to unveil the molecular basis of
frequently occurring disorders such as MA and MO. Both
linkage analyses and genome-wide association studies
(GWAS) tend to detect alleles of medium–small effect size
but high frequency. Linkage analyses investigate the co-
segregation of diseases with genetic markers within family
members. Although linkage methods proved to be extre-
mely successful in monogenic Mendelian diseases, their
power of detection is minimal when they are used to
explore the genetic bases of complex traits and multifac-
torial diseases (such as migraine) not showing a simple
Table 2 A short list of syndromic clinical conditions presenting with migraine headache
Syndromic migraine Gene (chromosome) involved Migraine features
Familial hemiplegic migraine (FHM) CACNA1 (19p13); ATP1A2 (1q23);
SCN1A (2q24); others unknown
Attacks of hemiplegic aura
Mitochondrial encephalomyopathy, lactic-acidosis,
stroke-like episodes (MELAS)
MTTL1 (mtDNA) Recurrent MA, focal neurological
deficits, vomiting, convulsions
Cerebral autosomal dominant arteriopathy with subcortical
infarcts and leukoencephalopathy (CADASIL)
NOTCH3 (19q13.2) MA/MO in 22–40 % of affected
patients
Retinopathy, vascular, cerebral and renal involvement,
Raynaud and migraine attacks (HERNS)
TREX1 (3p21.3) Migraine in most cases
MA migraine with aura, MO migraine without aura
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Mendelian pattern of transmission (refer also to the
detailed literature list cited in [58]). Most results prove to
be ‘‘false’’ positive, fail to be replicated in larger cohorts,
or are contradictory. Table 3 summarises several repro-
ducible studies in both autosomes and the X-chromosome
[58]. Despite sometimes being extremely rewarding (see
the identification of the TRESK gene [59]), few linkage
studies have been found to be replicable in independent
investigations and their findings have pointed generally to
broad genomic regions without clearly advancing our
understanding of the genetics of typical MA or MO. The
absence of clear biomarkers of disease status, the con-
founding role of spouses—spouses are generally sampled
as healthy family controls but could themselves have
contributed to the geno/phenotypes of their offspring—and
the use of different diagnostic methods (direct ascertain-
ment versus telephone interview) are able to explain only
partly the poor reproducibility of these studies [9]. The use
of more clearly defined individual features of migraine
(‘‘endophenotypes’’) or analyses in isolated populations
(see for reference the studies in Norfolk Island [60]) would
result in a more powerful approach, as would the use of
modern genetic technologies. One such approach is that of
genome-wide data mining on automatic array platforms in
which hundreds of thousands of single nucleotide poly-
morphic variants (SNPs) are simultaneously queried in
large populations of migraineurs and non-migraineurs.
GWAS have a high power to detect common variants of
high or moderate effect size. For variants with smaller
effect sizes (e.g. relative risk \ 1.2), the power is greatly
reduced, particularly for recessive loci. Excellent published
works have employed GWAS to identify genetic markers
specific for migraine (or its subtypes) compared with non-
migraine headache. For further discussion of this topic,
readers are referred to an outstanding review on GWAS
power and significance in migraine, published in this
journal earlier this year [9]. Even more recently, a GWAS
study identified the first susceptibility loci specific for MO,
thereby expanding our knowledge of this debilitating
neurological disorder [61]. Several attracting markers have
been pinpointed. Among these rs1835740 seems to mod-
ulate glutamate homeostasis, rs11172113 (in the LRP1
gene, belonging to the lipoprotein receptor family) may
also impact glutamate pathways through interaction with
NMDA glutamate receptors (Fig. 2), whereas rs10166942
(in TRPM8, encoding a cold and cold-induced burning pain
sensor necessary for nociception) [9] implicates a pain-
related pathway in migraine. Further work is required to
confirm that the identified SNPs (such as rs11172113 and
rs10166942 that have also been replicated in [61]) and
adjacent genes are causally related and relevant to
migraine. However, it is important to reiterate that GWAS
studies should be conducted on large samples and ensure
good clinical diagnosis and powerful technology and
statistics.
Certainly, with powerful whole-genome assay technol-
ogy rapidly becoming less expensive, the use of candidate
gene association studies within the migraine scientific
community seems superseded. That said, specific clinical
conditions or variants of endophenotypes, or even the
adoption of array-based platforms to assay multiple
‘‘attractive’’ or ‘‘hypothesis-drive’’ candidates in combi-
nation with rigorous meta-analyses, might still provide
useful information on individual phenotypes. This might be
true of variants in the glutamate receptor genes, or in
hormonal or insulin receptors, or in the gene encoding the
5,10-methylenetetrahydrofolate reductase enzyme. For a
more complete list, please refer to the conclusions of the
study cited as Ref. [62].
The outlook: next-generation migraine research
Technical advances in genomic sequencing are commonly
referred as next-generation sequencing (NGS). These
platforms are able to generate more sequence data and are
substantially less expensive than the original ‘‘capillary’’
Sanger methods. Moreover, in the bid to account for
structural variations, they can also handle more complex
and smaller genomes, copy number variants, and SNPs
[63]. Due to their cost-effectiveness and versatility, NGS
approaches are poised to emerge as a dominant genomics
technology in patient-oriented research. Specifically, there
is considerable interest in employing NGS platforms for
targeted sequencing of specific candidate genes and
sequencing of SNPs identified through GWAS. As an
example, targeted genomic enrichment approaches with
NGS enable deep sequencing of any complex genomic
region of interest, and may be a straightforward means of
detecting causal variants in common diseases, capable of
contributing to understanding of their pathogenesis. With
the falling cost of NGS technology, sequencing of the
Table 3 Loci identified in common forms of migraine and repro-
duced in independent studies (see reference [9] for details)
Chromosome locus Phenotype Methodology
1q22 MO Genome-wide scan
3p24 MO Genome-wide scan
4q21 MO Genome-wide scan
4q24 MA Genome-wide scan
5q21 Pulsating headache Linkage analyses
10q22–q23 MO/MA Linkage analyses
Xp22 MA Linkage analyses
Xq24–q28 MA/MO Regional microsatellite markers
MA migraine with aura, MO migraine without aura
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entire human exome in large numbers of individuals is now
feasible and promising [64].
We anticipate that in the near future, with the costs of tar-
geted multiplex amplicon enrichment also falling, NGS
applications will flourish the field of migraine genetics. It is to
be hoped, in particular, that this more intensive application
might bring particular advantages in terms of efforts to
improve the individual response to drug treatment, which is the
final goal of molecular genetic studies in migraine. Advances
have actually already been made in the field using more tra-
ditional ‘‘capillary’’ sequencing approaches. This is true in the
case of chronic migraine, a clinical [65] and pathophysiolog-
ical [66] challenge for headache researchers. For instance, the
serotonin pathway was intensely investigated in patients with
chronic migraine associated with medication overuse head-
ache (MOH) but none of the SNPs analysed in genes encoding
serotonin transporters and receptors 1A, 1B, 2A and 6 [67, 68]
could be firmly linked to the development of MOH. Con-
versely, genetic polymorphisms in MAO-A and CYP1A2
were found to be over-represented in MOH patients as com-
pared to sporadic migraineurs [69]. A polymorphism of the
brain-derived neurotrophic factor gene and a polymorphism of
the WFS1 gene (related to several psychiatric disorders) were
also found to be related to higher monthly analgesic intake
[70, 71]. Pending replication studies and meta-analyses, we
cannot draw solid conclusions about the existence of a genetic
determinant predisposing to chronicity [68]. Importantly,
given the high rate of patients not responding to common
prophylactic and symptomatic therapies, the use of modern
technologies (i.e. NGS) might fit well into recent pharmac-
ogenomic strategies [72, 73] that are addressing the issue of
how genetic determinants influence drug response. None-
theless, the complexity of this field is such that even higher
predictive power and careful clinical investigations will be
needed before applications can be translated into clinical
practice. The study of genetic factors of individual response
(pharmacogenomics) in terms of efficacy or adverse events to
prophylactic treatments [74] might be relevant in this regard.
It is, indeed, surprising that most studies focus only on
symptomatic therapies with only a handful [72, 75] being
devoted to the pharmacogenomics of effective preventive
management of migraine. NGS has the potential to fill the
knowledge gap in the pharmacogenomics of migraine, gen-
erating a positive fallout on daily clinical practice.
In conclusion, we expect to see an increase in under-
standing of the molecular genetics of migraine, even
though the disease itself does not really seem to be a
‘‘canonical’’ genetic condition. Novel molecular approa-
ches should increase our chances of finding answers to still
open questions, such as ‘‘how migraine attacks start’’ or
‘‘why headache occurs in MA and MO’’. Wider use of NGS
applications will not only scan the individual genome, with a
view to future personalised therapies, but also provide
information on epigenetic mechanisms, that is, modifications
in gene expression such as gene methylation that are heritable
but are not encoded in the DNA sequence. Although these
modifications do not impact on the nucleotide sequence of the
DNA, they have the potential to modulate gene expression
and influence molecular pathways. New research directions
are likely to focus on understanding the various factors (not
only genetic) that are well balanced in healthy subjects but
disturbed in migraineurs.
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